← All trials
NCT04585347
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2015
- Primary completion
- Nov 13, 2015
- Completion date
- Nov 13, 2015
- First posted
- Oct 14, 2020
- Last posted
- Oct 14, 2020
- Enrollment
- 12
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Alzheon Inc.Lead sponsor
- QuotientCollaborator
- QuotientStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.